[go: up one dir, main page]

WO2021203772A1 - Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof - Google Patents

Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof Download PDF

Info

Publication number
WO2021203772A1
WO2021203772A1 PCT/CN2021/000075 CN2021000075W WO2021203772A1 WO 2021203772 A1 WO2021203772 A1 WO 2021203772A1 CN 2021000075 W CN2021000075 W CN 2021000075W WO 2021203772 A1 WO2021203772 A1 WO 2021203772A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
compositions
phosphodiesterase
compounds
ectonucleotide pyrophosphatase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/000075
Other languages
French (fr)
Inventor
Bang Fu
Zhongxin SUN
Yinlong LI
Wei Ren
Lieming Ding
Jiabing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Priority to CN202180027402.9A priority Critical patent/CN115362150A/en
Publication of WO2021203772A1 publication Critical patent/WO2021203772A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of Formula (I), methods of using the compounds as ENPP1 inhibitors, and pharmaceutical compositions comprising such compounds.The compounds are useful in treating cancers and infectious diseases.

Description

ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 INHIBITORS, COMPOSITIONS AND USES THEREOF
Figure PCTCN2021000075-appb-000001
Figure PCTCN2021000075-appb-000002
Figure PCTCN2021000075-appb-000003
Figure PCTCN2021000075-appb-000004
Figure PCTCN2021000075-appb-000005
Figure PCTCN2021000075-appb-000006
Figure PCTCN2021000075-appb-000007
Figure PCTCN2021000075-appb-000008
Figure PCTCN2021000075-appb-000009
Figure PCTCN2021000075-appb-000010
Figure PCTCN2021000075-appb-000011
Figure PCTCN2021000075-appb-000012
Figure PCTCN2021000075-appb-000013
Figure PCTCN2021000075-appb-000014
Figure PCTCN2021000075-appb-000015
Figure PCTCN2021000075-appb-000016
Figure PCTCN2021000075-appb-000017
Figure PCTCN2021000075-appb-000018
Figure PCTCN2021000075-appb-000019
Figure PCTCN2021000075-appb-000020
Figure PCTCN2021000075-appb-000021
Figure PCTCN2021000075-appb-000022
Figure PCTCN2021000075-appb-000023
Figure PCTCN2021000075-appb-000024
Figure PCTCN2021000075-appb-000025
Figure PCTCN2021000075-appb-000026
Figure PCTCN2021000075-appb-000027
Figure PCTCN2021000075-appb-000028
Figure PCTCN2021000075-appb-000029
Figure PCTCN2021000075-appb-000030
Figure PCTCN2021000075-appb-000031
Figure PCTCN2021000075-appb-000032
Figure PCTCN2021000075-appb-000033
Figure PCTCN2021000075-appb-000034
Figure PCTCN2021000075-appb-000035
Figure PCTCN2021000075-appb-000036
Figure PCTCN2021000075-appb-000037
Figure PCTCN2021000075-appb-000038
Figure PCTCN2021000075-appb-000039
Figure PCTCN2021000075-appb-000040
Figure PCTCN2021000075-appb-000041
Figure PCTCN2021000075-appb-000042
Figure PCTCN2021000075-appb-000043
Figure PCTCN2021000075-appb-000044
Figure PCTCN2021000075-appb-000045
Figure PCTCN2021000075-appb-000046
Figure PCTCN2021000075-appb-000047
Figure PCTCN2021000075-appb-000048
Figure PCTCN2021000075-appb-000049
Figure PCTCN2021000075-appb-000050
Figure PCTCN2021000075-appb-000051
Figure PCTCN2021000075-appb-000052
Figure PCTCN2021000075-appb-000053
Figure PCTCN2021000075-appb-000054
Figure PCTCN2021000075-appb-000055
Figure PCTCN2021000075-appb-000056
Figure PCTCN2021000075-appb-000057
Figure PCTCN2021000075-appb-000058
Figure PCTCN2021000075-appb-000059
Figure PCTCN2021000075-appb-000060
Figure PCTCN2021000075-appb-000061
Figure PCTCN2021000075-appb-000062
Figure PCTCN2021000075-appb-000063
Figure PCTCN2021000075-appb-000064
Figure PCTCN2021000075-appb-000065
Figure PCTCN2021000075-appb-000066
Figure PCTCN2021000075-appb-000067
Figure PCTCN2021000075-appb-000068
Figure PCTCN2021000075-appb-000069
Figure PCTCN2021000075-appb-000070
Figure PCTCN2021000075-appb-000071
Figure PCTCN2021000075-appb-000072
Figure PCTCN2021000075-appb-000073
Figure PCTCN2021000075-appb-000074
Figure PCTCN2021000075-appb-000075
Figure PCTCN2021000075-appb-000076
Figure PCTCN2021000075-appb-000077
Figure PCTCN2021000075-appb-000078
Figure PCTCN2021000075-appb-000079
Figure PCTCN2021000075-appb-000080
Figure PCTCN2021000075-appb-000081
Figure PCTCN2021000075-appb-000082
Figure PCTCN2021000075-appb-000083
Figure PCTCN2021000075-appb-000084
Figure PCTCN2021000075-appb-000085
Figure PCTCN2021000075-appb-000086
Figure PCTCN2021000075-appb-000087
Figure PCTCN2021000075-appb-000088

Claims (1)

  1. Figure PCTCN2021000075-appb-100001
    Figure PCTCN2021000075-appb-100002
    Figure PCTCN2021000075-appb-100003
    Figure PCTCN2021000075-appb-100004
    Figure PCTCN2021000075-appb-100005
    Figure PCTCN2021000075-appb-100006
    Figure PCTCN2021000075-appb-100007
    Figure PCTCN2021000075-appb-100008
    Figure PCTCN2021000075-appb-100009
    Figure PCTCN2021000075-appb-100010
    Figure PCTCN2021000075-appb-100011
    Figure PCTCN2021000075-appb-100012
    Figure PCTCN2021000075-appb-100013
    Figure PCTCN2021000075-appb-100014
PCT/CN2021/000075 2020-04-09 2021-04-09 Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof Ceased WO2021203772A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180027402.9A CN115362150A (en) 2020-04-09 2021-04-09 ENPP1 inhibitor, composition and application thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/083944 2020-04-09
CN2020083944 2020-04-09
CN2020083926 2020-04-09
CNPCT/CN2020/083934 2020-04-09
CN2020083934 2020-04-09
CNPCT/CN2020/083926 2020-04-09

Publications (1)

Publication Number Publication Date
WO2021203772A1 true WO2021203772A1 (en) 2021-10-14

Family

ID=78024077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/000075 Ceased WO2021203772A1 (en) 2020-04-09 2021-04-09 Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof

Country Status (2)

Country Link
CN (1) CN115362150A (en)
WO (1) WO2021203772A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969943A (en) * 2022-04-28 2023-10-31 轩竹生物科技股份有限公司 Tri-cyclic diacylglycerol kinase inhibitors and uses thereof
US12029744B2 (en) 2019-04-12 2024-07-09 Riboscience Llc Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046778A1 (en) * 2017-08-31 2019-03-07 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2019051269A1 (en) * 2017-09-08 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University Enpp1 inhibitors and their use for the treatment of cancer
WO2019177971A1 (en) * 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2019191504A1 (en) * 2018-03-30 2019-10-03 Mavupharma, Inc. Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof
WO2020140001A1 (en) * 2018-12-28 2020-07-02 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
WO2020190912A1 (en) * 2019-03-19 2020-09-24 Stingray Therapeutics, Inc. Quinoline and quinazoline compounds and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190282703A1 (en) * 2018-03-13 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase (enpp) conjugates and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046778A1 (en) * 2017-08-31 2019-03-07 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2019051269A1 (en) * 2017-09-08 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University Enpp1 inhibitors and their use for the treatment of cancer
WO2019177971A1 (en) * 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2019191504A1 (en) * 2018-03-30 2019-10-03 Mavupharma, Inc. Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof
WO2020140001A1 (en) * 2018-12-28 2020-07-02 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
WO2020190912A1 (en) * 2019-03-19 2020-09-24 Stingray Therapeutics, Inc. Quinoline and quinazoline compounds and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029744B2 (en) 2019-04-12 2024-07-09 Riboscience Llc Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN116969943A (en) * 2022-04-28 2023-10-31 轩竹生物科技股份有限公司 Tri-cyclic diacylglycerol kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
CN115362150A (en) 2022-11-18

Similar Documents

Publication Publication Date Title
MX2022015812A (en) Inhibitors of cysteine proteases and methods of use thereof.
EP4516301A3 (en) Nitrile-containing compounds for use as medicaments
MX2020002183A (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof.
MA45920B1 (en) Pyridopyrimidinone cdk2 / 4/6 inhibitors
MX2021005350A (en) Pyridazinone compounds and uses thereof.
MX2023009185A (en) Benzamide compounds.
CN114072411A (en) Pyrimidine derivatives as Wee1 inhibitors
EP4248972A3 (en) Pyridazinone compounds and uses thereof
EA201101650A1 (en) NEW PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF MALIGNANT NONFORMS AND THE FOLLOWING DISEASES
WO2021262826A3 (en) 1&#39;-cyano nucleoside analogs and uses thereof
JOP20180009A1 (en) Hiv inhibitor compounds
WO2019152419A8 (en) Prc2 inhibitors
MX379459B (en) Bromodomain inhibitors
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MA54653B1 (en) Modulators of the cxcr7 piperidine receptor
MX2022011601A (en) Substituted oxoisoindoline compounds for the treatment of cancer.
TW200637614A (en) Bendamustine pharmaceutical compositions
MA40225B1 (en) Substituted dihydroisoquinolinone compounds
AU2020231934A8 (en) Compounds useful in HIV therapy
CN115515949A (en) Novel aminopyrimidine EGFR inhibitors
MX2021006619A (en) Tyrosine kinase inhibitors, compositions and methods there of.
WO2021203772A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof
CR20240043A (en) Heteroaryl compounds for treating huntington&#39;s disease
MX2022013401A (en) Azalactam compounds as hpk1 inhibitors.
PH12020551994A1 (en) Tlr7 agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21784058

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21784058

Country of ref document: EP

Kind code of ref document: A1